Major Depressive Disorder
📧 Sign up to get email alerts when something new happens for Major Depressive Disorder.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2021-12-13FDA Approved: BUPROPION HYDROCHLORIDE (SR) — Supplemental Application (ScieGen Pharmaceuticals, Inc.)
FDA approved ScieGen Pharmaceuticals' supplemental application for a sustained-release generic version of bupropion hydrochloride, with the …
-
FDA approval · 2021-12-10FDA Approved: ESCITALOPRAM OXALATE — Supplemental Application (Amneal Pharmaceuticals LLC)
The FDA has approved a supplemental application for Escitalopram Oxalate from Amneal Pharmaceuticals, indicating an approval of a new generi…
-
FDA approval · 2021-12-10FDA Approved: ESCITALOPRAM OXALATE — Supplemental Application (Macleods Pharmaceuticals Limited)
FDA approved a supplemental application for escitalopram oxalate submitted by Macleods Pharmaceuticals Limited. The action updates the appro…
-
CLINICAL_TRIALS trial_result · 2021-12-08Clinical Trial Update: A Pilot Study on Effect of add-on Sulforaphane to SSRIs and Application of Niacin Skin Flush Response Test in Major Depressive Disorder [Phase 4]
Pilot Phase 4 study examining add-on sulforaphane to SSRIs with niacin skin flush test in major depressive disorder.
-
CLINICAL_TRIALS trial_result · 2021-12-06Clinical Trial Update: A Comparative Study on Efficacy and Safety of add-on Sulforaphane or rTMS to Escitalopram for Major Depressive Disorder With Poor Response to Initial Treatment [Phase 4]
A Phase 4 clinical trial comparing add-on sulforaphane or rTMS to escitalopram for major depressive disorder with poor initial treatment res…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2021-12-03Clinical Trial Update: Study of Desvenlafaxine in Treating Major Depressive Disorder. [Phase 3]
A Phase 3 clinical trial evaluating desvenlafaxine for major depressive disorder has completed.
-
CLINICAL_TRIALS trial_result · 2021-12-03Clinical Trial Update: Support for Perinatal Adherence and Depression [NA]
A completed clinical trial at Massachusetts General Hospital evaluated perinatal adherence and depression in people with HIV, with results p…
-
CLINICAL_TRIALS trial_result · 2021-12-01Clinical Trial Update: Remote Training in Evidence-based Practices for Clinicians Who Work With Migrant Workers [NA]
A terminated clinical trial evaluating remote training in evidence-based practices for clinicians working with migrant workers, focusing on …
-
CLINICAL_TRIALS trial_result · 2021-11-30Clinical Trial Update: iTBS for Adolescent Depression: An Open Label Study Evaluating Safety and Efficacy of Treatment [NA]
Open-label study evaluating the safety and efficacy of intermittent theta-burst stimulation (iTBS) for adolescent depression; completed with…
-
FDA approval · 2021-11-24FDA Approved: OLANZAPINE AND FLUOXETINE — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
The FDA approved Teva's supplemental application for a generic olanzapine and fluoxetine fixed-dose combination product. This approval corre…
-
FDA approval · 2021-11-24FDA Approved: OLANZAPINE AND FLUOXETINE — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
The FDA approved Teva's supplemental application for the olanzapine and fluoxetine combination product, expanding the regulatory status for …
-
CLINICAL_TRIALS trial_result · 2021-11-18Clinical Trial Update: Vortioxetine as a Novel Anti-depressant With Improvement in Cognitive Abilities [Phase 3]
Phase 3 clinical trial update for vortioxetine as a novel antidepressant showing improvement in cognitive abilities.
-
CLINICAL_TRIALS trial_result · 2021-11-17Clinical Trial Update: Adjunctive Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment [Phase 3]
Phase 3 trial evaluating adjunctive pimavanserin for major depressive disorder with inadequate response to antidepressants has completed and…
-
CLINICAL_TRIALS trial_result · 2021-11-15Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Ansofaxine Hydrochloride Extended-release Tablets in the Treatment of Major Depressive Disorder (MDD) [Phase 3]
Phase 3 trial evaluating the efficacy and safety of Ansofaxine hydrochloride extended-release tablets for major depressive disorder has been…
-
CLINICAL_TRIALS trial_result · 2021-11-15Clinical Trial Update: A Trauma-Informed Approach for Positive Youth Development for Montana Students [NA]
A completed clinical trial from Montana State University investigating a trauma-informed approach to positive youth development for Montana …
-
FDA approval · 2021-11-12FDA Approved: DOXEPIN — Supplemental Application (North Star Rx LLC)
The FDA approved a supplemental application for doxepin submitted by North Star Rx LLC. The approval updates the product's labeling.
-
FDA approval · 2021-11-12FDA Approved: QUETIAPINE — Supplemental Application (Lupin Pharmaceuticals, Inc.)
The FDA approved Lupin Pharmaceuticals' supplemental application for a generic quetiapine product (ANDA204203). This marks a supplemental ap…
-
CLINICAL_TRIALS trial_result · 2021-11-12Clinical Trial Update: Study of Ammoxetine Hydrochloride Enteric-coated Tablets in Subjects With Depression [Phase 2]
Phase 2 trial update for Ammoxetine hydrochloride enteric-coated tablets in major depressive disorder is reported with unknown status.
-
FDA approval · 2021-11-10FDA Approved: PRISTIQ EXTENDED-RELEASE — Supplemental Application (Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.)
The FDA approved a supplemental application for Pristiq Extended-Release (desvenlafaxine succinate) from Wyeth Pharmaceuticals (Pfizer).
-
CLINICAL_TRIALS trial_result · 2021-11-10Clinical Trial Update: Internet-based CBT After Stroke Pilot [NA]
A completed pilot trial evaluating internet-based cognitive behavioral therapy after stroke for depression.
-
CLINICAL_TRIALS trial_result · 2021-11-10Clinical Trial Update: Screening Wizard, Component 1 of iCHART (Integrated Care to Help At-Risk Teens)-Feasibility/Pilot Phase [NA]
Feasibility/pilot study update for Screening Wizard, a component of iCHART targeting at-risk teens with depression and suicidal ideation; st…
-
FDA approval · 2021-11-09FDA Approved: QUETIAPINE FUMARATE — Supplemental Application (Macleods Pharmaceuticals Limited)
The FDA approved a supplemental application for quetiapine fumarate from Macleods Pharmaceuticals Limited, enabling a generic version of the…
-
CLINICAL_TRIALS trial_result · 2021-11-08Clinical Trial Update: Adolescent Mindfulness Mobile App Study (RCT) [NA]
A completed adolescent mindfulness mobile app randomized trial for rumination and depression with results posted.
-
FDA approval · 2021-11-02FDA Approved: QUETIAPINE FUMARATE — Supplemental Application (Unichem Pharmaceuticals (USA), Inc.)
FDA approved a supplemental application for Quetiapine Fumarate from Unichem Pharmaceuticals (USA), Inc. The action approves changes to the …
-
FDA approval · 2021-11-02FDA Approved: PAROXETINE — Original Application (Chartwell RX, LLC.)
FDA approved a generic paroxetine product under an original ANDA submitted by Chartwell RX, LLC.